A

Aquestive Therapeutics Inc
NASDAQ:AQST

Watchlist Manager
Aquestive Therapeutics Inc
NASDAQ:AQST
Watchlist
Price: 3.31 USD Market Closed
Market Cap: 403.8m USD

Net Margin

-158.8%
Current
Declining
by 82.2%
vs 3-y average of -76.7%

Net Margin shows how much profit a company keeps from each dollar of sales after all expenses, including taxes and interest. It reflects the company`s overall profitability.

Net Margin
-158.8%
=
Net Income
$-68.9m
/
Revenue
$43.4m

Net Margin shows how much profit a company keeps from each dollar of sales after all expenses, including taxes and interest. It reflects the company`s overall profitability.

Net Margin
-158.8%
=
Net Income
$-68.9m
/
Revenue
$43.4m

Peer Comparison

Country Company Market Cap Net
Margin
US
Aquestive Therapeutics Inc
NASDAQ:AQST
402.7m USD
Loading...
US
Eli Lilly and Co
NYSE:LLY
982.2B USD
Loading...
UK
Dechra Pharmaceuticals PLC
LSE:DPH
440.4B GBP
Loading...
US
Johnson & Johnson
NYSE:JNJ
526.1B USD
Loading...
CH
Roche Holding AG
SIX:ROG
273.2B CHF
Loading...
UK
AstraZeneca PLC
LSE:AZN
210.7B GBP
Loading...
CH
Novartis AG
SIX:NOVN
219.9B CHF
Loading...
US
Merck & Co Inc
NYSE:MRK
270.7B USD
Loading...
DK
Novo Nordisk A/S
CSE:NOVO B
1.7T DKK
Loading...
IE
Endo International PLC
LSE:0Y5F
218B USD
Loading...
US
Pfizer Inc
NYSE:PFE
145.8B USD
Loading...
No Stocks Found

Market Distribution

Lower than 87% of companies in the United States of America
Percentile
13th
Based on 15 072 companies
13th percentile
-158.8%
Low
-4 418 600% — -9.6%
Typical Range
-9.6% — 11.3%
High
11.3% — 1 135 400%
Distribution Statistics
the United States of America
Min -4 418 600%
30th Percentile -9.6%
Median 3.1%
70th Percentile 11.3%
Max 1 135 400%

Aquestive Therapeutics Inc
Glance View

Aquestive Therapeutics, Inc. engages in the identifying, developing, and commercializing differentiated products to address unmet medical needs and to solve patients’ therapeutic problems. The company is headquartered in Warren, New Jersey and currently employs 157 full-time employees. The company went IPO on 2018-07-25. The firm is engaged in developing orally administered products to deliver molecules, providing alternatives to care therapies. The company is engaged in advancing a late-stage product pipeline focused on treating diseases of the central nervous system (CNS), and an earlier stage pipeline for the treatment of severe allergic reactions, including anaphylaxis. The firm's CNS portfolio, which is focused on epilepsy includes Sympazan and Libervant. The active programs in its complex molecule pipeline portfolio are: AQST-109-SF, AQST-108-SF, and AQST-108-SF. Its PharmFilm technology develops medicines that offer non-invasive delivery, customized suitability for patients with dysphagia, or trouble swallowing, can be administered without water and ensures consistent therapeutic dosing. PharmFilm is comprised of polymer compositions that serve as film formers to hold active pharmaceutical ingredients (APIs) and excipients in place.

AQST Intrinsic Value
2.53 USD
Overvaluation 23%
Intrinsic Value
Price
A
What is Net Margin?
Net Margin shows how much profit a company keeps from each dollar of sales after all expenses, including taxes and interest. It reflects the company`s overall profitability.
How is Net Margin calculated?

Net Margin is calculated by dividing the Net Income by the Revenue.

Net Margin
-158.8%
=
Net Income
$-68.9m
/
Revenue
$43.4m
What is Aquestive Therapeutics Inc's current Net Margin?

The current Net Margin for Aquestive Therapeutics Inc is -158.8%, which is below its 3-year median of -76.7%.

How has Net Margin changed over time?

Over the last 3 years, Aquestive Therapeutics Inc’s Net Margin has decreased from -147.7% to -158.8%. During this period, it reached a low of -158.8% on Oct 30, 2025 and a high of -15.6% on Dec 31, 2023.

Back to Top